Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Details)

v3.24.2.u1
Segment reporting (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Jun. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Jun. 30, 2024
USD ($)
segment
Jun. 30, 2023
USD ($)
Segment reporting            
Number of reportable segments | segment         1  
Revenue $ 128,231   $ 5,130   $ 133,909 $ 52,731
Total operating expenses (59,531)   (50,038)   (114,470) (95,983)
Operating profit/(loss) 68,700   (44,908)   19,439 (43,252)
Interest income 1,376   1,543   2,721 2,219
Interest expense (526)       (526)  
Gain on bargain purchase     22,155     22,155
Other income (expense), net 497   501   436 (170)
Income tax expense (526)   (680)   (1,052) (1,305)
Net profit/(loss) attributable to ordinary shareholders 69,521 $ (48,503) (21,389) $ 1,036 21,018 (20,353)
Research            
Segment reporting            
Total operating expenses (3,830)   (3,499)   (7,438) (5,373)
CMC and Quality            
Segment reporting            
Total operating expenses (14,159)   (13,675)   (28,933) (26,608)
Biomarkers            
Segment reporting            
Total operating expenses (2,495)   (1,222)   (5,286) (2,452)
Development and Compliance            
Segment reporting            
Total operating expenses (12,611)   (8,647)   (27,486) (19,037)
Infrastructure management and facilities            
Segment reporting            
Total operating expenses (7,749)   (6,126)   (15,828) (13,490)
Commercial planning            
Segment reporting            
Total operating expenses (2,561)   (778)   (6,445) (1,426)
Support functions            
Segment reporting            
Total operating expenses (9,139)   (14,074)   (21,073) (28,635)
Other            
Segment reporting            
Total operating expenses $ (6,987)   $ (2,017)   $ (1,981) $ 1,038